ARA-290 (Cibinetide): What Is It and What Are Its Potential Benefits?

ARA-290 is a small, laboratory-made peptide that researchers are studying for its possible effects on damaged nerves and injured tissues. Its other name is cibinetide.

A peptide is a short chain of amino acids—the building blocks that also make up proteins. ARA-290 contains 11 amino acids.

Scientists designed it using part of the structure of erythropoietin, usually called EPO. EPO is a hormone best known for helping the body make red blood cells. ARA-290 was designed to copy some of EPO’s tissue-protective activity without stimulating red blood cell production. [1]

Much of the human research has focused on small-fiber neuropathy, a type of damage to small nerves. Early findings are encouraging in some areas, but they do not establish ARA-290 as a proven treatment. [2, 4]

Researchers propose that ARA-290 activates a system on certain cells called the innate repair receptor.

In simple terms, this receptor is thought to help cells respond to injury. Activating it may influence signals involved in inflammation, cell survival and repair.

Scientists are investigating whether ARA-290 can help:

• Reduce harmful inflammatory activity.
• Protect stressed cells from damage.
• Support the recovery of injured tissues.

These are proposed biological effects supported by experimental research. They do not mean that ARA-290 repairs every kind of tissue damage in people. [7, 1]

Small nerves help us feel pain, heat and cold. Some also help control automatic body functions.

When these nerves are damaged, symptoms can include:

• Burning pain.
• Tingling or pins and needles.
• Numbness.
• Pain from light touch.
• Unusual sensitivity to temperature.

This condition is called small-fiber neuropathy. It can occur in people with diabetes, sarcoidosis and other conditions. [23, 24, 22]

Sarcoidosis is an inflammatory disease that can affect different organs. Some people with sarcoidosis develop small-fiber neuropathy, which is why this group has been included in several ARA-290 studies. [25, 2]

1. Supporting Small-Nerve Recovery

One of the most interesting research findings concerns changes in small nerve fibers.

Some human studies have measured nerves in the cornea, the clear front surface of the eye. Researchers can examine these nerves using special imaging equipment.

A 64-person study in people with sarcoidosis found that one ARA-290 treatment group had a significant improvement in corneal nerve fiber area compared with placebo. That group also showed an increase in a marker of growing nerve fibers in the skin.

However, the improvement was not statistically significant across all treatment groups. A better nerve measurement also does not automatically mean less pain or complete nerve recovery. [4]

2. Possibly Reducing Neuropathy Symptoms

Early studies suggest ARA-290 may improve some symptoms associated with small-fiber neuropathy.

A small placebo-controlled trial involving 22 people with sarcoidosis reported improvements in neuropathy-related symptoms. Another study reported symptom improvements alongside increased corneal nerve fiber density. [2, 3]

The pain findings are less consistent.

In the later 64-person trial, pain improved in every group, including the placebo group. The reported additional pain improvement in a subgroup receiving ARA-290 did not reach statistical significance.

ARA-290 may have effects on nerve health, but reliable pain relief has not been established. [4]

3. Potential Effects on Diabetes-Related Nerve Problems

Researchers have also studied ARA-290 in people with type 2 diabetes and painful neuropathy.

An early controlled study reported improvements in:

• A questionnaire measuring neuropathy symptoms.
• HbA1c, a marker of average blood sugar.
• Blood fat measurements.
• Corneal nerve density in a subgroup with more pronounced nerve loss.

The study was short and exploratory. Its results do not establish ARA-290 as a treatment for diabetes or its complications. [5]

4. Reducing Inflammation

Inflammation is part of the body’s response to injury. However, excessive or ongoing inflammation can contribute to tissue damage.

Animal studies have investigated whether ARA-290 reduces inflammatory activity around damaged nerves. Some found changes in inflammation-related cells or signals alongside improvements in pain behavior. [12, 20]

This helps explain the scientific interest in ARA-290. It does not establish it as a general anti-inflammatory treatment for people.

5. Protecting Injured Tissues

Researchers have investigated related tissue-protective effects in experimental models of:

• Kidney injury.
• Heart damage.
• Brain injury.

Some studies reported reduced damage or improved function in animals. These findings help researchers decide what to investigate next, but they cannot confirm benefits in people with kidney disease, heart disease or brain injuries. [15, 16, 19]

These areas have different levels of evidence. The most directly relevant human findings concern small-fiber neuropathy; broader organ-protection claims rely mainly on preclinical research. [4, 5, 15, 16]

Yes. Researchers have studied cibinetide for diabetic macular edema, a condition involving swelling in the part of the retina responsible for detailed central vision.

A small study recruited nine people. It did not find an average improvement in vision or central retinal thickness, although some individual and questionnaire results suggested areas for further investigation.

This study did not demonstrate that ARA-290 improves eyesight. [6]

It is also important to distinguish two different things:

• Measuring corneal nerves to study neuropathy.
• Treating retinal disease to improve vision.

Positive findings in corneal nerve measurements do not prove a benefit for eyesight.

ARA-290 was designed from part of EPO’s structure, but the two should not be treated as interchangeable.

The lack of red-blood-cell stimulation is an important design feature. It does not prove that ARA-290 is free from side effects. [1]

Some small clinical studies reported no clear treatment-related safety concerns during their observation periods. The diabetic eye study reported no serious adverse events or reactions. [5, 6]

However, small studies cannot reliably identify uncommon side effects. Short studies also cannot establish the safety of repeated or long-term use.

Questions remain about:

• Uncommon adverse reactions.
• Long-term effects.
• Interactions with other medicines.
• Safety in populations not adequately studied.

Several publications also disclose involvement by researchers connected with the company developing cibinetide. That does not invalidate the findings, but independent confirmation would strengthen confidence in them. [6]

Cibinetide received EU orphan designation for sarcoidosis.

Orphan designation supports the development of potential medicines for rare conditions. It is not marketing approval and does not prove that a medicine works. The EMA explicitly distinguishes orphan designation from authorization to market a medicine. [21]

The European Respiratory Society’s sarcoidosis guidelines discussed cibinetide as an investigational approach. They did not make a formal recommendation for its use and highlighted the need for further research into safety and effectiveness. [10]

ARA-290 has a scientific basis worth investigating, but several gaps remain.

The human studies are relatively small. A result involving a few dozen participants may not apply to everyone with nerve damage.

Many studies are short. Researchers need to know whether improvements last and whether longer exposure changes the safety picture.

Measurements and symptoms can tell different stories. An increase in nerve fibers is interesting, but people also need meaningful improvements in pain, daily function and quality of life.

Results from one condition may not apply to another. Findings in sarcoidosis-related neuropathy do not establish benefits for every cause of tingling, numbness or nerve pain. [4, 2, 10]

What is ARA-290 in simple terms?

ARA-290 is an experimental peptide designed to copy part of EPO’s tissue-protective activity without stimulating red blood cell production. Researchers are studying its effects on nerve damage and inflammation. [1]

Are ARA-290 and cibinetide the same thing?

Yes. Cibinetide and ARA-290 refer to the same compound. Scientific articles may also use the name pyroglutamate helix B surface peptide, or pHBSP. [21, 7]

What are the potential benefits of ARA-290?

The main areas of research include small-nerve recovery, neuropathy symptoms, inflammation and tissue protection. Human evidence is most relevant to specific forms of small-fiber neuropathy, and the benefits remain uncertain. [4, 5]

Does ARA-290 help with nerve pain?

Some early trials reported symptom improvements, but pain results are mixed. The larger sarcoidosis trial did not establish a clear overall pain-relief benefit compared with placebo. [2, 4]

Can ARA-290 regenerate nerves?

Some studies found improvements in nerve fiber measurements and markers associated with nerve growth. These findings suggest possible repair-related effects, but they do not prove complete nerve regeneration or recovery of normal function. [4]

Does ARA-290 raise red blood cell counts?

It was designed to avoid the red-blood-cell-stimulating activity of EPO. Foundational experimental research supports that distinction. [1]

Can ARA-290 treat diabetes?

It is not established as a diabetes treatment. One early study reported improvements in certain metabolic measurements and neuropathy symptoms, but those findings need confirmation. [5]

Does ARA-290 improve vision?

A small diabetic macular edema study did not show an average improvement in vision. Improvements in corneal nerve measurements in other studies should not be interpreted as proof of better eyesight. [6, 4]

Is ARA-290 safe for long-term use?

Long-term safety has not been established by the small, short studies discussed here. Their findings cannot rule out uncommon or delayed adverse effects. [5, 6, 10]

Is there an established ARA-290 dosage?

The studies used different experimental regimens for specific research questions. They do not establish a standard dose for self-treatment, and trial regimens should not be treated as personal dosing instructions. [2, 4]

Does orphan designation mean ARA-290 is approved?

No. Orphan designation supports research and development for a rare condition. Marketing authorization requires a separate assessment of quality, safety and effectiveness. [21]

1. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.
2. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
3. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
4. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
5. ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
6. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.
7. Flipping the molecular switch for innate protection and repair of tissues.
8. Targeting the innate repair receptor to treat neuropathy.
9. ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
10. ERS clinical practice guidelines on treatment of sarcoidosis.
11. ARA290 produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.
12. ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.
13. ARA290 reverses mechanical allodynia in the neuritis model.
14. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel.
15. ARA290 attenuates renal ischemia/reperfusion injury.
16. A small nonerythropoietic helix B surface peptide is cardioprotective against ischemic myocardial damage.
17. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.
18. ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats.
19. Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide.
20. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis.
21. European Medicines Agency: Cibinetide orphan designation for sarcoidosis.
22. Foundation for Sarcoidosis Research: Small Fiber Neuropathy & ARA-290 Results.
23. NINDS: Peripheral Neuropathy.
24. NIDDK: Peripheral Neuropathy.
25. NHLBI: What Is Sarcoidosis?.